RSS

TEPI Patch technology

European Pharmaceutical Manufacturer editor, Felicity Thomas, sits down with Sally Waterman, COO at Medherant to discuss the benefits of transdermal drug delivery and how industry developments and changes in patient needs are leading to a shift… more

, Opinion

Here, we talk with David Davies, whose appointment as the new head of development at Medherant marks the company’s move into clinical development of the ibuprofen TEPI Patch. more

Opinion

Medherant — a company focused on transdermal drug delivery — has revealed that it has raised £3.8 million in its latest funding round, which will support the company as it progresses its ibuprofen TEPI Patch into clinical development early next year more

News

Medherant, developer of transdermal drug delivery patches, has been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards. more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Developer of next-generation transdermal drug delivery patches, Medherant, has signed an agreement with a Japanese transdermal patch company to evaluate the potential of the TEPI Patch technology. more

Technology

University of Warwick spin-out company that is developing a transdermal drug delivery patch technology, Medherant, has been shortlisted for the Royal Society of Chemistry (RSC) Emerging Technologies Competition 2017. more

News

Medherant, a University of Warwick spin-out company, developing transdermal drug delivery patch technology, has announced the appointment of Sheryl Caswell as head of clinical development. more

News